{"url":"https://newsforagent.com/news/2026-11-17/novartis-cosentyx-fda-approval-pmr","markdown_url":"https://newsforagent.com/news/2026-11-17/novartis-cosentyx-fda-approval-pmr.md","title":"Novartis Wins FDA Approval for Cosentyx in PMR","headline":"Novartis Cosentyx Becomes First Anti-IL-17 Biologic Approved by FDA for Polymyalgia Rheumatica","description":"Novartis won FDA approval for Cosentyx 150 mg in polymyalgia rheumatica, the first anti-IL-17 biologic for the disease.","section":"Regulation & Approvals","published_at":"2026-11-17T03:17:47+00:00","modified_at":"2026-11-17T03:17:47+00:00","author":"News Desk","key_takeaways":["The FDA approved Cosentyx (secukinumab) 150 mg for adults with polymyalgia rheumatica who had an inadequate response to corticosteroids or cannot tolerate a steroid taper.","In the Phase III REPLENISH trial, 40.5% of patients on Cosentyx 150 mg achieved sustained remission at Week 52 versus 20.5% on placebo.","The approval is the 11th US indication for Cosentyx, which is already approved for PMR in the EU, with reviews ongoing including in Japan."],"companies":[{"name":"Novartis","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00000js/novartis","website":"https://www.novartis.com"}],"source":{"publisher":"GlobeNewswire","title":"Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)","url":"https://www.globenewswire.com/news-release/2026/11/17/3404251/0/en/novartis-cosentyx-becomes-first-and-only-fda-approved-anti-il-17-biologic-for-people-with-polymyalgia-rheumatica-pmr.html"},"other_sources":[],"tags":["Regulation & Approvals","Novartis"],"body_markdown":"Novartis said on November 17, 2026 that the US Food and Drug Administration approved Cosentyx (secukinumab) 150 mg for adults with polymyalgia rheumatica who have had an inadequate response to corticosteroids or cannot tolerate a corticosteroid taper. The [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/17/3404251/0/en/novartis-cosentyx-becomes-first-and-only-fda-approved-anti-il-17-biologic-for-people-with-polymyalgia-rheumatica-pmr.html) release describes it as the first and only anti-IL-17 biologic approved for the condition.\n\n## What the Cosentyx PMR Approval Covers\n\n[Novartis](https://akta.pro/company-profiles/00000js/novartis) is a Basel-headquartered pharmaceutical company that develops prescription medicines in oncology, immunology, cardiovascular and renal care, and neuroscience. Cosentyx is a fully human biologic that inhibits interleukin-17A, and the new label covers adults with PMR, an inflammatory disease that mainly affects people over 50 and is marked by acute pain and stiffness in the shoulders, neck and hips.\n\nThe approval rests on the pivotal Phase III REPLENISH trial (NCT05767034), a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group study run across 27 countries. Patients were randomized to Cosentyx 300 mg, Cosentyx 150 mg or placebo, all with a 24-week steroid taper. At Week 52, 40.5% of patients on Cosentyx 150 mg achieved sustained remission versus 20.5% on placebo. Serious adverse events occurred in 15.9% of the Cosentyx 150 mg group and 14.2% of the placebo group.\n\n\"The FDA approval of secukinumab in PMR marks a significant advancement for patients and physicians,\" said Prof. John Stone, global principal investigator for REPLENISH. Victor Bultó, President, US, Novartis, said the approval is \"our 11th US indication for Cosentyx.\" The company said about 966,000 people in the United States live with PMR, and that relapses affect up to 40% of patients in the first year.\n\n## Novartis Funding and Deal Records\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Novartis has three funding rounds on record, including a $2 billion post-IPO debt round in May 2026 and a $2.5 billion post-IPO debt round in June 2024. The same records list total funding of $4.5 billion and a revenue estimate of $5 billion+.\n\n## Earlier Cosentyx Regulatory Steps\n\nOn November 13, 2026, Novartis said the EMA's CHMP gave a positive opinion for Cosentyx in adolescents aged 12 and older with moderate to severe hidradenitis suppurativa, according to TradingView. If approved, it would be the only IL-17A inhibitor for that indication in Europe. On November 14, 2026, Novartis said two new products and three new indications were added to the medical insurance drug catalog, Jiemian reported.\n\n## Japan Review After the US Approval\n\nNovartis said it filed the REPLENISH data for regulatory review in Japan, in addition to other countries. The company said Cosentyx is already approved for PMR in the EU and that additional regulatory reviews are ongoing.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}